KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gains from Investment Securities (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Gains from Investment Securities for 15 consecutive years, with $11.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 76.19% to $11.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 92.06% decrease, with the full-year FY2025 number at $4.2 million, down 92.06% from a year prior.
  • Gains from Investment Securities was $11.8 million for Q4 2025 at Supernus Pharmaceuticals, up from -$3.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $49.7 million in Q4 2024 to a low of -$20.5 million in Q3 2021.
  • A 5-year average of $5.9 million and a median of $713000.0 in 2022 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 1591.71% in 2024; the steepest drop was 3675.22% in 2024.
  • Supernus Pharmaceuticals' Gains from Investment Securities stood at $25.0 million in 2021, then crashed by 39.02% to $15.2 million in 2022, then skyrocketed by 209.23% to $47.1 million in 2023, then grew by 5.56% to $49.7 million in 2024, then tumbled by 76.19% to $11.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Gains from Investment Securities are $11.8 million (Q4 2025), -$3.8 million (Q3 2025), and -$11.4 million (Q2 2025).